Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
37 Results for "
CCNE1
" in MedChemExpress (MCE) Product Catalog:
Products (37)
37 Results for "CCNE1" in MCE Product Catalog:
9
9 Publications Verification
Synonyms: RP-6306
lunresertib (RP-6306) is a potent, selective and orally active PKMYT1 inhibitor with an IC50 of 14 nM. lunresertib shows a high degree of selectivity over other kinases in cellular binding assays. lunresertib shows anticancer effects [1].
2
Cirtociclib (BLU-222) is an orally active and highly selective CDK2 inhibitor. Cirtociclib disrupts Rb signaling and causes G1 arrest and apoptosis in CCNE1-amplified endometrial cancer cells [1] .
1
1 Cited Publications
Cat. No.: HY-162255
CAS No.: 2488073-20-5
CDK2-IN-23 (Compound 17) is a kinase selective and highly potent CDK2 inhibitor (IC50 = 0.29 nM). CDK2-IN-23 shows the pharmacodynamic inhibition of CDK2 in CCNE1-amplified mouse models. CDK2-IN-23 can be used for the research of cancer [1].
Cat. No.: HY-175842
CAS No.: 3030279-55-8
CDK2 degrader 7 is an orally active CDK2 degrader, with DC50 values of 13 nM (MKN1cells) and 17 nM (TOV21G cells). CDK2 degrader 7 induces G1 phase arrest in MKN1 cells. CDK2 degrader 7 achieves tumor stasis in HCC1569 (CCNE1-amplified) xenograft models. CDK2 degrader 7 can be used for the study of CCNE1-amplified cancers [1].
Cat. No.: HY-164827
CAS No.: 2862772-71-0
Target:
Research Areas:
CDK2 degrader 3 is a selective CDK2 molecular glue-like degrader. CDK2 degrader 3 induces G1 cell cycle arrest in CCNE1-amplified cancer cells. CDK2 degrader 3 is applicable to breast cancer-related research [1].
Cat. No.: HY-159805
CAS No.: 2813260-27-2
CDK2-IN-31 is a CCNE1:CDK2 complex inhibitor with an IC50 of 0.13 μM. CDK2-IN-31 binds to a cryptic allosteric pocket at the CCNE1:CDK2 interface, inducing structural rearrangements of the CDK2 A-loop that disrupt the kinase's active conformation and interfere with substrate binding. CDK2-IN-31 inhibits phosphorylation of retinoblastoma protein 1 (RB1) in CCNE1-dependent ovarian cancer cells. CDK2-IN-31 impairs coenrichment of protein PRC1 with CCNE1-N112C:CDK2 complexes. CDK2-IN-31 can be used for the research of ovarian cancer [1].
Cat. No.: HY-RS02127
Target:
Research Areas:
CCNE1 Human Pre-designed siRNA Set A contains three designed siRNAs for CCNE1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-175819
CAS No.: 717094-37-6
PD-166285 is a PKMYT1 inhibitor, with an IC50 value of 17 nM. PD166285 shows strong antiproliferative effects against CCNE1-amplified OVCAR3 cells (IC50 = 0.14 μM) and HCC1569 cells (IC50 = 0.21 μM). PD166285 induces apoptosis and arrests CCNE1-amplified HCC1569 cells at the G1/S phase of the cell cycle. PD166285 can be used for the research of PKMYT1-targeted therapies for CCNE1-amplified cancers [1].
Cat. No.: HY-RS17273
Target:
Research Areas:
Ccne1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ccne1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-186127
CAS No.: 3116573-90-8
CCNE1 degrader-1 (I-2) is a degrader targeting CCNE1. CCNE1 degrader-1 can be used in cancer-related research [1].
Cat. No.: HY-RS23727
Target:
Research Areas:
Ccne1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ccne1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-170442
CAS No.: 3054692-62-2
Synonyms: CDK2-IN-37
ECI830 (CDK2-IN-37) is an orally active, ATP-competitive and highly selective CDK2 inhibitor. ECI830 shows high selectivity over other CDK family members. ECI830 can be used for the study of HR+/HER2- breast cancer and CCNE1-amplified tumors (such as ovarian cancer and lung cancer) [1].
Cat. No.: HY-186126
CAS No.: 3066623-95-5
CDK2 modulator 1 is a CDK2 modulator with an EC50 < 100 nM and an Emax > 100% of positive control in a TR-FRET proximity assay. CDK2 modulator 1 induces ternary complex formation with CDK2/CCNE1 and CRBN. CDK2 modulator 1 can be used for the research of cancer [1].
Cat. No.: HY-P74214
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: CCNE; CCNE1; Cyclin E1; G1/S-specific cyclin-E1
Species:
Source:
Cat. No.: HY-180485
PROTAC D16-M1P2 is an orally active CRBN-mediated selective PKMYT1 PROTAC degrader, with a DC50 of 0.7 nM in CCNE1-amplified HCC1569 breast cancer cells. PROTAC D16-M1P2 induces PKMYT1 degradation via the ubiquitin-proteasome system, directly inhibits PKMYT1 kinase activity, suppresses Thr14 phosphorylation of CDK1, and depends on functional CRBN and ubiquitination-like modification processes. PROTAC D16-M1P2 can be used for the research of CCNE1-amplified breast cancer, FBXW7-mutated cholangiocarcinoma, and PPP2R1A-deficient cancers [1] .
Cat. No.: HY-181131
CAS No.: 1310059-06-3
Anticancer agent 300 (compound P14) is a CCND1, CDK4, CDK6, and CCNE1 modulator, with anti-proliferative, cell-cycle modulatory, senescence-inducing, and apoptosis-inducing activity. Anticancer agent 300 can be used for the research of ER+/HER2− breast cancer and BRAF-mutant melanoma [1].
Cat. No.: HY-184649
CAS No.: 2922859-30-9
CDK2-IN-60 is an orally active, ATP-competitive selective CDK2 inhibitor with a Ki of 77 pM. CDK2-IN-60 has high selectivity for both CDK4 and CDK1. CDK2-IN-60 blocks G1/S cell cycle progression to suppress proliferation of CCNE1-amplified tumor cells. CDK2-IN-60 serves as a lead chemical probe for investigating CCNE1-amplified cancers and CDK4/6 inhibitor-resistant HR-positive breast cancer [1].
Cat. No.: HY-P74257
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: Cyclin-dependent kinase 1; CDK1; CDC2; G1/S-specific cyclin-E1; CCNE1
Species:
Source:
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
